Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Dietrich-Ntoukas, T; Cursiefen, C; Westekemper, H; Eberwein, P; Reinhard, T; Bertz, H; Nepp, J; Lawitschka, A; Heiligenhaus, A; Seitz, B; Messmer, EM; Meyer-ter-Vehn, T; Basara, N; Greinix, H; Datiles, MB; Lee, SJ; Pavletic, SZ; Wolff, D.
Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD.
Cornea. 2012; 31(3): 299-310.
Doi: 10.1097/ICO.0b013e318226bf97
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Ocular chronic graft-versus-host disease (cGVHD) is one of the most frequent long-term complications after hematopoietic stem cell transplantation and is often associated with significant morbidity and reduced quality of life. The German/Austrian/Swiss Consensus Conference on Clinical Practice in cGVHD aimed to summarize the currently available evidence for diagnosis and (topical) treatment and to summarize different treatment modalities of ocular cGVHD. The presented consensus was based on a review of published evidence and a survey on the current clinical practice including transplant centers from Germany, Austria, and Switzerland. Ocular cGVHD often affects the lacrimal glands, the conjunctiva, the lids (including meibomian glands), and the cornea but can also involve other parts of the eye such as the sclera. Up to now, there have been no pathognomonic diagnostic features identified. The main therapeutic aim in the management of ocular cGVHD is the treatment of inflammation and dryness to relieve patients' symptoms and to maintain ocular integrity and function. Therapy should be chosen in the context of the patient's overall condition, systemic immunosuppressive therapy, symptoms, ocular surface integrity, and inflammatory activity. The consensus conference proposed new grading criteria and diagnostic recommendations for general monitoring of patients with graft-versus-host-disease for use in clinical practice. The evidence levels for diagnosis and treatment of ocular cGVHD are low, and most of the treatment options are based on empirical knowledge. Topical immunosuppression, for example, with cyclosporine, represents a promising strategy to reduce inflammation and dryness in ocular cGVHD. Further clinical trials are necessary to elucidate risk factors for eye manifestation, complications, and visual loss and to evaluate staging criteria and diagnostic and therapeutic measures for ocular cGVHD.
- Find related publications in this database (using NLM MeSH Indexing)
- Adrenal Cortex Hormones - therapeutic use
- Anti-Inflammatory Agents - therapeutic use
- Anti-Inflammatory Agents -
- Chronic Disease -
- Eye Diseases - diagnosis Eye Diseases - drug therapy
- Eye Diseases -
- Graft vs Host Disease - complications Graft vs Host Disease - diagnosis Graft vs Host Disease - drug therapy
- Hematopoietic Stem Cell Transplantation - adverse effects
- Humans -
- Immunosuppressive Agents - therapeutic use
- Quality of Life -
- Quality of Life -
- Find related publications in this database (Keywords)
- ocular graft-versus-host disease
- chronic graft-versus-host disease
- dry eye syndrome
- consensus diagnosis and treatment
- hematopoietic stem cell transplantation